Maxime Meloche1,2,3, Michael Khazaka1,4, Imad Kassem1, Amina Barhdadi1,2, Marie-Pierre Dubé2,3,5, Simon de Denus1,2,3. 1. Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada. 2. Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Quebec, Canada. 3. Montreal Heart Institute, Montreal, Quebec, Canada. 4. Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. 5. Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Abstract
AIMS: CYP2D6 genetic polymorphisms are associated with metoprolol pharmacokinetics. Whether the clinical response to metoprolol is also affected remains uncertain. METHODS: We conducted a systematic review on the effects of CYP2D6 polymorphism on the clinical response to metoprolol. Searches were conducted using MEDLINE. Meta-analyses were performed on the impact of CYP2D6-inferred phenotypes on heart rate (HR) reduction, diastolic (DBP) and systolic (SBP) blood pressure reduction, average daily doses, all-type adverse events and bradycardia. RESULTS: Our qualitative assessment indicated inconsistent results in individual studies and endpoints, but CYP2D6 poor metabolizers (PM) generally presented a greater reduction in HR. The meta-analysis of 15 studies, including a total of 1146 individuals, found a reduction in HR of 3 beats/min (P = .017), and of SBP and DBP by 3 mmHg (P = .0048) for PM compared to non-PM individuals using similar metoprolol doses. Bradycardia appeared more frequent by 4-fold for PM, although significant heterogeneity was observed regarding bradycardia, which limits the scope of this finding. CONCLUSION: Patients without any CYP2D6 metabolic capacities appear to have increased reduction in DBP, HR and SBP during metoprolol treatment and may be at a higher risk of bradycardia compared to patients with active CYP2D6 phenotypes. Further prospective data are required to determine whether CYP2D6 is associated with clinical events in patients treated with metoprolol, as well as to demonstrate the clinical utility of an individualized approach of prescribing metoprolol using CYP2D6-inferred phenotypes.
AIMS: CYP2D6 genetic polymorphisms are associated with metoprolol pharmacokinetics. Whether the clinical response to metoprolol is also affected remains uncertain. METHODS: We conducted a systematic review on the effects of CYP2D6 polymorphism on the clinical response to metoprolol. Searches were conducted using MEDLINE. Meta-analyses were performed on the impact of CYP2D6-inferred phenotypes on heart rate (HR) reduction, diastolic (DBP) and systolic (SBP) blood pressure reduction, average daily doses, all-type adverse events and bradycardia. RESULTS: Our qualitative assessment indicated inconsistent results in individual studies and endpoints, but CYP2D6 poor metabolizers (PM) generally presented a greater reduction in HR. The meta-analysis of 15 studies, including a total of 1146 individuals, found a reduction in HR of 3 beats/min (P = .017), and of SBP and DBP by 3 mmHg (P = .0048) for PM compared to non-PM individuals using similar metoprolol doses. Bradycardia appeared more frequent by 4-fold for PM, although significant heterogeneity was observed regarding bradycardia, which limits the scope of this finding. CONCLUSION:Patients without any CYP2D6 metabolic capacities appear to have increased reduction in DBP, HR and SBP during metoprolol treatment and may be at a higher risk of bradycardia compared to patients with active CYP2D6 phenotypes. Further prospective data are required to determine whether CYP2D6 is associated with clinical events in patients treated with metoprolol, as well as to demonstrate the clinical utility of an individualized approach of prescribing metoprolol using CYP2D6-inferred phenotypes.
Authors: Jasmine A Luzum; Kevin M Sweet; Philip F Binkley; Tara J Schmidlen; Joseph P Jarvis; Michael F Christman; Wolfgang Sadee; Joseph P Kitzmiller Journal: Pharm Res Date: 2017-02-08 Impact factor: 4.200
Authors: J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar Journal: Clin Pharmacol Ther Date: 2011-03-16 Impact factor: 6.875
Authors: Thomas Rau; Roland Heide; Klaus Bergmann; Henrike Wuttke; Ulrike Werner; Nico Feifel; Thomas Eschenhagen Journal: Pharmacogenetics Date: 2002-08
Authors: R Koytchev; R G Alken; V Vlahov; V Kirkov; R Kaneva; U Thyroff-Friesinger; E Rehak Journal: Eur J Clin Pharmacol Date: 1998-08 Impact factor: 2.953
Authors: Andrea Gaedigk; Katrin Sangkuhl; Michelle Whirl-Carrillo; Greyson P Twist; Teri E Klein; Neil A Miller Journal: Clin Pharmacol Ther Date: 2018-12-07 Impact factor: 6.875
Authors: Li Li; Lu Yu; Huan He; Li Wei; Zigang Xu; Libo Zhao; Yujuan Sun; Bin Zhang; Yuanxiang Liu; Rui He; Xiaoling Wang; Lin Ma Journal: Front Pediatr Date: 2022-05-02 Impact factor: 3.569
Authors: Philip S Bernard; Whitney Wooderchak-Donahue; Mei Wei; Steven M Bray; Kevin C Wood; Baiju Parikh; Gwendolyn A McMillin Journal: Cancers (Basel) Date: 2021-03-11 Impact factor: 6.639